Article

Smoking may lead to a greater risk of surgery for TED

Author(s):

Current smokers with Graves' Disease had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression.

an image of a female smoking a cigarette. (Image Credit: AdobeStock/mitarart)

Smoking was associated with an increased risk of surgical intervention for treating thyroid eye disease (TED). (Image Credit: AdobeStock/mitarart)

Researchers from the Departments of Ophthalmology Boston Children’s Hospital, and Massachusetts Eye and Ear, Harvard Medical School, Boston, reported that smoking was associated with an increased risk of surgical intervention for treating thyroid eye disease (TED) in the Intelligent Research in Sight (IRIS) Registry.1

The authors undertook a retrospective cohort study that included adults with Graves’ disease in the IRIS Registry from January 1, 2013, to December 31, 2020. The primary outcome was the need for surgery to treat TED, ie, orbital decompression, strabismus surgery, and eyelid recession surgery.

This study included 87,774 patients (mean age, 59 years;81% women).

The results showed that current smokers had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression (3.7% vs 1.9%; p < 0.001), strabismus surgery (4.6% vs 2.2%; p < 0.001), and eyelid recession (4.1% vs 2.6%; p < 0.001).

After adjusting for demographic factors (age, sex, race, ethnicity, and geographic region), those who currently smoked were at greater risk of undergoing orbital decompression, strabismus surgery, and eyelid recession (p < 0.001 for all comparisons) than those who never smoked. Former smokers were at higher risk of having to undergo each of the surgeries, but the risk was lower than that associated with current smoking.

The authors concluded, “Smoking was associated with increased risk of surgical intervention for TED in the IRIS Registry. Former smokers were at a lower risk than current smokers, supporting the role of smoking cessation in lowering the burden of surgical disease at the population level.”

Reference:
  1. Oke I, Reshef ER, Elze T, et al. Smoking is associated with a higher risk of surgical intervention for thyroid eye disease in the IRIS Registry. Am J Ophthalmol. 2023;249:174-82; Published online January 19, 2023; DOI: https://doi.org/10.1016/j.ajo.2023.01.020

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.